Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Solid Biosciences (SLDB) Invested Capital (2017 - 2024)

Solid Biosciences' Invested Capital history spans 8 years, with the latest figure at $170.4 million for Q3 2024.

  • For Q3 2024, Invested Capital rose 18.05% year-over-year to $170.4 million; the TTM value through Sep 2024 reached $170.4 million, up 18.05%, while the annual FY2023 figure was $126.5 million, 40.25% down from the prior year.
  • Invested Capital for Q3 2024 was $170.4 million at Solid Biosciences, down from $193.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $253.0 million in Q1 2021 and bottomed at $22.2 million in Q3 2020.
  • The 5-year median for Invested Capital is $170.4 million (2024), against an average of $161.5 million.
  • The largest annual shift saw Invested Capital tumbled 79.52% in 2020 before it surged 904.74% in 2021.
  • A 5-year view of Invested Capital shows it stood at $132.1 million in 2020, then surged by 57.63% to $208.2 million in 2021, then grew by 1.66% to $211.7 million in 2022, then tumbled by 40.25% to $126.5 million in 2023, then surged by 34.74% to $170.4 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Invested Capital are $170.4 million (Q3 2024), $193.2 million (Q2 2024), and $210.7 million (Q1 2024).